Comparison of a new hemostatic device for gastric endoscopic submucosal dissection: Prospective, Randomized trial for Coajet vs.Hemograsper

Aims Gastric endoscopic submucosal dissection (ESD) is often accompanied by bleeding. Coajet is a new useful device for hemostasis through monopolar contact and has an injection needle inside. Therefore, this study was conducted to evaluate the effectiveness and safety of a new hemostatic device comparing to hemostatic forceps.

Methods This prospective, randomized, single center study has enrolled consecutive patients who were candidates for gastric ESD from Feb. 2022. The Hemograsper group (HG) had underwent hemostasis by conventional method and the Coajet (CG) was used for a marking of lesion and submucosal injection in initial stage of ESD and then for hemostasis.

Results A total 39 patients were enrolled (HG, n = 20, CG, n =19). Baseline characteristics between the two groups showed no significant difference in terms of age, sex, diagnosis, locations, endoscopic sizes, and morphology. There were no difference in total operation time (minutes, HG 14.86 ± 6.51 vs. CG 12.11 ± 7.82, p = 0.24) and hemostatic time (seconds, HG 168.3 ± 70.58 vs. CG 130.4 ± 94.22, p = 0.16). The procedure related other variables such as complete en bloc resection rate, admission days, grade of immediate bleeding, and delayed bleeding within 30days (HG n=1 vs. CG n=2) showed no difference.

Conclusions A new hemostatic device Coajet showed comparable efficacy to conventional hemostatic forceps for bleeding control and prevention of delayed bleeding in gastric ESD.

Publikationsverlauf

Artikel online veröffentlicht:
14. April 2023